Bespoke Extracts, Inc.

BSPK
About the company

Bespoke Extracts, Inc., together with its subsidiary, Bespoke Extracts Colorado, LLC, produces and sells pre-rolled marijuana cigarettes in the United States. The company owns, manufactures, and distributes a diverse portfolio of cannabis consumer packaged goods under the Fresh Joints, Doobskis, DutchBlunts, and Wee Joints brand names.

Country: United StatesPrice: $0.00Market Cap: $6,752

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

2 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedPASSFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Annual history · FY 2024

Latest source filing: 2025-11-12

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-21

Score computed: 2026-11-14

Annual history · FY 2024 · Balance sheet at 2025-09-30 · TTM ended 2025-09-30

Latest source filing: 2025-11-12

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-21

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-21

Score computed: 2026-11-14

Annual history · FY 2024 · TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Market data at 2026-11-01

Latest source filing: 2025-11-12

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024 · TTM ended 2025-09-30 · Balance sheet at 2025-09-30

Latest source filing: 2025-11-12

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2025-04-21

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment · Balance sheet at 2025-09-30

Latest source filing: 2025-11-12

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-04-21

Score computed: 2026-11-14

Annual history · FY 2024 · TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Market data at 2026-11-01

Latest source filing: 2025-11-12

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2025-09-30

Latest source filing: 2025-11-12

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-04-21

Score computed: 2026-11-14

TTM ended 2025-09-30 · Balance sheet at 2025-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2024

Latest source filing: 2025-11-12

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-21

Score computed: 2026-11-14

Annual history · FY 2024 · Balance sheet at 2025-09-30

Latest source filing: 2025-11-12

Score computed: 2026-11-14

TTM ended 2025-09-30 · Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-11-12

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 2✗ 26▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-387.8%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-387.8%, ROC=N/A (invested capital <= 0)
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per ShareN/A (negative BVPS)
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation Reasonableness
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-13178.3%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical Average
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low120% of trailing low ($0.00)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-10819.96%; #6246/6340 (top 98.5%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization-384.4058; #6410/6449 (top 99.4%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+210.7593; #64/5247 (top 1.2%)
      ✓OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-13178.35%; #4479/4519 (top 99.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-99.74%; #6173/6202 (top 99.5%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      FCF Positive and Growing$-0.9M
      ✗LynchPositive and growing
      Operating Cash Flow$-0.3M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-80.71%, ROA=-288.92%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-13178.3%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/3 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-13296.6%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/14 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-0.9M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-13178.35%; #4479/4519 (top 99.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Profitability6% pass✓ 5✗ 30▾

      15 of 16 flag BSPK's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)1/16 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)1/16 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-98.4%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-89.0% (latest)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROEN/A (negative equity)
      ✗Lynch> 15%
      EBIT / Enterprise Value-387.8%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-387.8%, ROC=N/A (invested capital <= 0)
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-288.92%
      ✗PiotroskiROA > 0
      ROA Change YoY-418.46% -> -288.92% (delta: +129.54%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-80.71%, ROA=-288.92%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY43.7% -> 40.5%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-51.3%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity
      ✗Dreman> 12%
      Margin of Safety
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-130.2% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency1/14 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-45.0%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-118011.6% (2022) -> -89.0% (2024)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 66.3% -> 40.5%, operating margin -118011.6% -> -89.0%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-10819.96%; #6246/6340 (top 98.5%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+227.25%; #27/3702 (top 0.7%)
      ✓AsnessTop 30% of eligible cross-section
      Net income / positive book equity
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-9.9352; #5691/5884 (top 96.7%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years1/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Verdicts7% pass✓ 1✗ 13▾

      Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS

      Overall verdict
      ✗GrahamFAIL (0/9)✗BuffettFAIL (0/9)✗LynchFAIL (0/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 5)✗DremanFAIL (0/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✗AckmanFAIL (2/9)✗TempletonFAIL (3/8)✗SleepFAIL (2/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage8% pass✓ 1✗ 14▾

      11 of 12 flag BSPK's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: N/A (negative equity), IC: -16.6x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / EquityN/A (negative equity)
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities0.11
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt LevelsN/A (non-positive equity)
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-16.6x, D/EBITDA=N/A (D&A unavailable)
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section
    • Growth13% pass✓ 3✗ 10▾

      7 of 8 flag BSPK's growth — Graham, Lynch, Dreman +4 more

      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: 105.9% vs Rev: 42.3%
      ✗LynchInventory growth < Revenue growth
      EPS Growth Direction$0.00 (2011) -> $-0.10 (2024)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency1/14 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth42.3%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency2/5 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 66.3% -> 40.5%, operating margin -118011.6% -> -89.0%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR78.2%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency13% pass✓ 2✗ 9▾

      7 of 8 flag BSPK's efficiency — Graham, Buffett, Greenblatt +4 more

      Current Ratio0.11
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)-32.6%
      ✗Buffett> 10%
      ROIC - WACC-42.6%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)
      ✗Greenblatt> 25%
      Current Ratio Change YoY0.08 -> 0.15
      ✓PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY2.22x -> 3.11x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities0.11
      ✗Dreman> 1.5
      Return on Invested CapitalN/A (non-positive invested capital)
      ✗Munger> 15%
      ROIC (high and growing)FY2022: ROIC=unavailable; FY2023: ROIC=unavailable; FY2024: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/1 years above 12% (latest -30.6%)
      ✗SleepROIC > 12% in a majority of years

    Business & financials

    Financial snapshot: annual FY 2024. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Pharmaceutical Products
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Micro Cap($6,752)
    Revenue: $1.1M+42.3% YoY
    Net Income: $1.0M+30.0% YoY

    Financial Snapshot

    Operating Margin-89.0%
    Return on Equity49.6%
    Debt / Equity-0.15
    Current Ratio0.15
    EPS (Diluted)$-0.10
    Shares Retired−9.7% / −12.1% 2y

    Shareholder Return

    Fiscal 2024

    Issued 9.7% of shares last year, 12.1% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2025-09-30

    2024-10-01 – 2025-09-30

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, capex.

    Q3 FY 2025

    2025-07-01 – 2025-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q2 FY 2025

    2025-04-01 – 2025-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q1 FY 2025

    2025-01-01 – 2025-03-31

    Sources
    FY 2024
    Sources
    • 10-K · 2025-04-21
    FY 2023
    Sources
    • 10-K · 2025-04-21
    FY 2022
    Sources
    • 10-K · 2023-04-27
    FY 2021
    Sources
    • 10-K · 2021-12-13
    FY 2020
    Sources
    • 10-K · 2020-12-18
    Market Cap$6.8Kcurrent------$1.3Mest.$1.0Mest.$611.7Kest.$9.5Mest.$691.1Mest.
    Revenue$1.4M$467.9K↑69%$390.6K↑40%$263.2K↑1%$1.1M↑42%$785.5K↑22954%$3.4K↓90%$35.6K↑342%$8.1K
    Operating Income-$640.3K-$53.9K↑79%-$162.0K↑35%-$245.3K↑19%-$994.6K↑32%-$1.5M↑63%-$4.0M↓316%-$965.6K↑76%-$4.0M
    Net Income-$730.6K-$78.1K↑72%-$205.1K↑21%-$260.5K↑17%-$1.0M↑30%-$1.5M↑64%-$4.1M↓326%-$965.6K↑79%-$4.6M
    EPS (Diluted)--$-0.01↑67%$-0.02↑33%$-0.02↑33%$-0.10↑33%$-0.15↑66%$-0.44↓132%$-0.19↓375%$-0.04
    Gross Margin47.2%50.0%↑21%50.6%↑33%42.1%↑7%40.5%↓7%43.7%↓34%66.3%↑7%61.8%↑10%56.5%
    Operating Margin-45.0%-11.5%↑88%-41.5%↑54%-93.2%↑20%-89.0%↑53%-187.4%↑100%-118011.6%↓4247%-2714.9%↑95%-49857.5%
    ROE28.1%———49.6%↓42%86.0%↓86%612.4%↑1362%-48.5%↓105%903.5%
    Total Debt$194.0K$194.0K↑676%$184.0K↓81%$2.2M↑132%$310.0K↓64%$849.5K↑104%$415.5K↓17%$500.0K$500.0K
    Shareholders' Equity-$2.6M-$2.6M↓11%-$2.5M↓17%-$2.3M↓18%-$2.1M↓21%-$1.7M↓157%-$672.1K↓134%$2.0M↑487%-$513.7K
    Current Ratio0.110.11↑46%0.10↑23%0.10↑29%0.15↑95%0.08↓41%0.13↓99%9.71↑4881%0.19
    Debt / Equity-0.07-0.07↓596%-0.07↑84%-0.93↓96%-0.15↑70%-0.49↑20%-0.62↓346%0.25↑126%-0.97
    Operating Cash Flow-$259.7K-$19.6K↑31%-$31.0K↓10%-$72.9K↑25%-$289.8K↑30%-$415.2K↑48%-$798.1K↑23%-$1.0M↓124%-$465.2K
    Free Cash Flow---$19.6K-$31.0K-$672.9K-$889.8K---$805.3K↑23%-$1.0M--

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Pharmaceutical Products

    BSPK vs Peers — Financial Grading

    Revenue$1.1MBottom 25%
    Net Income$1.0MMedian
    ROE49.6%Top 25%
    D/E-0.15Top 25%
    Op. Margin-89.0%Bottom 25%
    Curr. Ratio0.15Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
    ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
    BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
    BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
    REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
    IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
    NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
    Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11